Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 TrialCOVID-19 백신 접종에서 Elecsys Anti-SARS-CoV-2 S 어세이의 임상적 유용성: mRNA-1273 1상 시험의 탐색적 분석Clinical Trial Published on 2022-01-192022-09-11 Journal: Frontiers in Immunology [Category] 임상, 치료기술, [키워드] 2019-nCoV absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-SARS-CoV-2 S antibody antibody levels automated baseline choice clinical clinical utility collected coronavirus correlated correlation COVID-19 Day detectable dose Elecsy ELISA ELISAs first vaccination geometric mean geometric mean concentration healthy heterogeneous humoral immune response increases in injection International international standard mRNA mRNA-1273 nanoluciferase neutralization test neutralization tests Neutralizing antibodies participant Participants Phase 1 phase 1 trial Protein pseudovirus neutralizing antibody pseudovirus neutralizing antibody assay quantification Quantitative quantitative serology RBD RBD ELISA RBD-specific antibodies RBD-specific antibody Receptor binding domain respiratory Result Roche S-2P Sample SARS-CoV-2 second vaccination Seroconversion seroconverted severe acute respiratory syndrome Coronavirus shown specific antibodies specificity Spike protein the Spike U/mL vaccination Vaccine vaccine-induced antibody response WHO [DOI] 10.3389/fimmu.2021.798117 PMC 바로가기 [Article Type] Clinical Trial
Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 20202019년 12월부터 2020년 12월까지 노르웨이 임산부의 SARS-CoV-2에 대한 항체 유병률Short Paper Published on 2022-01-132022-09-11 Journal: Epidemiology and Infection [Category] 진단, 치료기술, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted analysed antenatal care antibodies antibody Antigen Compliance coronavirus detect DiaSorin Elecsy Elecsys Epidemiology estimating explained first trimester hospital IgG immunoassay incidence modelling Norway Occurrence positive test result pregnant pregnant women Prevalence prevalence of disease preventive measure preventive measures remained respiratory Roche Diagnostics S1/S2 S2 protein SARS SARS CoV SARS CoV-2 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleocapsid SARS-CoV-2 virus sera serological seropositive serum severe acute respiratory syndrome Coronavirus study period syphilis test results the epidemic the SARS-CoV-2 virus women [DOI] 10.1017/S0950268822000073 PMC 바로가기 [Article Type] Short Paper
Performance of a flow cytometry-based immunoassay for detection of antibodies binding to SARS-CoV-2 spike proteinArticle Published on 2022-01-122022-10-04 Journal: Scientific Reports [Category] 진단, 치료기술, [키워드] antibodies binding antibody CLIA clinical sensitivity collected convalescent COVID-19 diagnosis of SARS-CoV-2 Elecsy expressing full-length highest IgG immunoassay individual Infection Infectious diseases Infectious-disease diagnostics Microbiology onset of symptom performance positive positive result returned Roche Roche Diagnostics S protein SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2-specific antibodies sera serological serum/plasma specimen T cell USA Virology [DOI] 10.1038/s41598-021-04565-1 PMC 바로가기 [Article Type] Article
Analytical and Clinical Evaluation of the Semiquantitative Elecsys Anti-SARS-CoV-2 Spike Protein Receptor Binding Domain Antibody Assay on the Roche cobas e602 AnalyzerRoche cobas e602 분석기에서 반정량적 Elecsys Anti-SARS-CoV-2 스파이크 단백질 수용체 결합 도메인 항체 분석의 분석 및 임상 평가Article Published on 2022-01-062022-09-11 Journal: American journal of clinical pathology [Category] SARS, 진단, 치료기술, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Analyzer Anti-spike anti-spike antibodies antibodies antibody Bilirubin Biotin clinical clinically Concordance coronavirus COVID-19 COVID-19 patient COVID-19 vaccination cross-reactivity detect diagnostics Elecsy ELISA enzyme-linked immunosorbent enzyme-linked immunosorbent assay evaluate evaluated exhibit greater hemoglobin IgA antibodies IgA antibody IgG IgM immunoassay Interference Lateral flow device linearity measure mRNA Neutralization assay PCR positivity plasma Precision Protein Receptor binding domain respiratory robust Roche SAR-CoV-2 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 virus Semiquantitative semiquantitatively Sensitivity and specificity serology Seropositivity serum spike Spike protein triglycerides turn [DOI] 10.1093/ajcp/aqab092 PMC 바로가기 [Article Type] Article
Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab오크렐리주맙으로 치료받은 다발성 경화증 환자에서 SARS-CoV-2 백신 접종에 대한 체액 및 T 세포 반응Article Published on 2022-01-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] MERS, SARS, 진단, 치료기술, [키워드] Absolute lymphocyte count adaptive Adaptive Biotechnology age analyzed anti-CD20 therapy Anti-SARS-CoV-2 S antibodies antibody Antibody Response B and T-cell BMI CD19 characterized chemotherapeutic agents cohort study comparator conducted coronavirus coronavirus vaccine COVID COVID-19 COVID-19 epidemic Descriptive statistics detectable determine did not produce Efficacy Elecsy Eligible patients enrolled Enrollment evaluate Fisher Fisher's exact test had no humoral Humoral response IgG immune response immunoassay immunogenicity Immunoglobulin Immunoglobulin G immunosuppressive impair Infection likelihood lymphocyte Multiple multiple sclerosis Natalizumab negative antibody response no correlation Ocrelizumab Patient patients patients treated positive positive antibody response post vaccination Prevent producing question raise reduce Research response Roche SAR-CoV-2 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination severity Sex shown single center T-cell T-cell Response T-cell responses Test the antibody response treated Treatment vaccination Vaccine vaccine immunogenicity variable was performed were excluded Wilcoxon rank sum [DOI] 10.1016/j.msard.2021.103382 PMC 바로가기 [Article Type] Article
Low Serological Prevalence of SARS-CoV-2 Antibodies in Cancer Patients at a German University Oncology Center독일 대학 종양학 센터의 암 환자에서 SARS-CoV-2 항체의 낮은 혈청학적 유병률Article Published on 2022-01-012022-09-11 Journal: Oncology research and treatment [Category] MERS, SARS, 진단, 치료기술, [키워드] active cancer acute respiratory syndrome acute respiratory syndrome coronavirus analyzed Antibody testing Cancer cancer patient Cancer patients cancer type center Chemotherapy coronavirus coronavirus disease Coronavirus disease 2019 Coronavirus disease-19 seroprevalence COVID-19 COVID-19 biobank diagnosed Diagnosis effort Elecsy Elecsys enrolled Epidemiology Europe faster German oncology center Germany hospital Immunity malignancy oncology palliative treatment Pancreatic cancer pandemic Patient patients Patients with cancer Prevalence prevalent preventive measure preventive measures respiratory risk of infection SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-COV-2 infection sera serological Severe acute respiratory syndrome coronavirus type 2 single-center Support the patient Treatment university vaccination vaccination rates [DOI] 10.1159/000520572 PMC 바로가기 [Article Type] Article
SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients간경변 및 이식 환자에서 2차 예방접종 후 SARS-CoV 2 특이 체액 및 T 세포 면역 반응Article Published on 2022-01-012022-09-12 Journal: Clinical gastroenterology and hepatology : the off [Category] SARS, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome age anti-S anti-SARS-CoV-2 anti-SARS-CoV-2 titer Arterial hypertension booster vaccinations cirrhosis Cohort Control controls coronavirus develop DiaSorin Effect Elecsy Euroimmun healthy control Heterologous humoral identify immune response immunoassay Immunosuppression immunosuppressive information inhibitor less LIAISON liver Liver cirrhosis liver transplant recipients Logistic regression analysis monotherapy Odds ratio Patient patient groups predictor prospective cohort study RBD recipient recipients reduction regimen Research response Roche routine SARS-CoV-2 SARS-CoV-2 vaccination second second vaccination Seroconversion Serological testing spike-protein spike-specific T-cell response T-cell T-cell Response Transplant trimer vaccination was performed [DOI] 10.1016/j.cgh.2021.09.003 PMC 바로가기 [Article Type] Article
SARS-CoV-2 Seroprevalence in Western Romania, March to June 20212021년 3월~6월 서부 루마니아의 SARS-CoV-2 혈청 유병률Article Published on 2021-12-262022-09-10 Journal: Medicina [Category] 치료법, [키워드] age antibodies Community confirmed COVID-19 case COVID-19 determine Elecsy Epidemiology female group immunoassay indicate individuals Laboratory magnitude male material no significant difference nucleocapsid protein Prevalence Rapid reported Romania Sample SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 seroprevalence Seroprevalence serum significant difference significantly higher Spread target tested total antibodies total antibody virus virus transmission [DOI] 10.3390/medicina58010035 PMC 바로가기 [Article Type] Article
SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assaysComirnaty(BNT162b2, BioNTech/Pfizer) 1회 또는 2회 투여 후 SARS-CoV-2 중화 항체: 동역학 및 화학발광 분석과의 비교Article Published on 2021-12-012022-09-12 Journal: Clinica chimica acta; international journal of cli [Category] MERS, SARS, 진단, [키워드] 2019-nCoV ACE age antibody assays BNT162b2 BNT162b2 vaccine Chemiluminescent assay circulating antibody CLIA Comirnaty correlated correlation COVID-19 cut-off difference dose Elecsy elicit evaluated FIVE Gender HCW healthcare worker IgG immune immunoassay immunoassays Immunological response Interaction Kinetics NAb titer neutralizing antibody no significant difference plaque reduction neutralization PRNT Protective S-RBD SARS-CoV-2 SARS-CoV-2 neutralizing antibody SARS-CoV-2 vaccine serology seropositive subjects threshold [DOI] 10.1016/j.cca.2021.10.028 PMC 바로가기 [Article Type] Article
Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study프랑스의 취약한 인구에서 COVID-19 전염병의 첫 번째 물결 이후 항 SARS-CoV-2 항체의 혈청 유병률: 횡단면 연구Article Published on 2021-11-232022-09-12 Journal: BMJ Open [Category] MERS, SARS, 진단, [키워드] 95% CI adjusted anti-SARS-CoV-2 antibody Community conditions COVID-19 COVID-19 case COVID-19 pandemic cross-sectional Elecsy Epidemiology Factor First wave France Health higher odd highest highlight identify immunoassay investigated lockdown logistic regressions multivariable pandemic preventive measure public health questionnaire reported symptom Roche SARS-CoV-2 antibody SARS-CoV-2 antibody testing SARS-COV-2 infection secondary outcome seropositive Seroprevalence social determinant stratified univariable working [DOI] 10.1136/bmjopen-2021-053201 PMC 바로가기 [Article Type] Article